DocGo Inc. (DCGO) Earnings Call Transcript & Summary
August 17, 2026
Earnings Call Speaker Segments
Mike Cole
executiveThanks, operator. Ahead of handing things over to management, I want to share a few comments about forward-looking statements. Everything we say on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar expressions might be used to flag those forward-looking statements; such statements don't guarantee future performance, and we can't promise that our plans, intentions, outcomes, results, or expectations will be achieved or realized. By their nature, forward-looking statements carry substantial risks, uncertainties, and assumptions, a great many of which lie beyond our control and could lead our actual results or outcomes, or when results or outcomes occur, to differ materially from what our forward-looking statements contain. Among these risks, uncertainties, and assumptions are, without limitation, those covered in risk factors and other sections of DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, the earnings release for this quarter, and additional reports and statements DocGo has filed with the SEC, which you are encouraged to review. Actual outcomes and results, or their timing, could differ materially from what such forward-looking statements express or imply. Today's call also cites non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures appear in our earnings release and the current report on Form 8-K containing our earnings release, which is available on our website, docgo.com, and has been filed with the SEC. What is said on this call is accurate only as of the date discussed. Investors shouldn't assume statements will stay relevant and operative later on. We assume no duty to update anything discussed on this call to reflect events or circumstances arising after this call's date, or to reflect new information or the occurrence of unanticipated events, except to the extent the law requires. With that, I'm happy to hand the call to Mr. Lee Bienstock, DocGo's CEO. Lee, please go ahead.
Lee Bienstock
executiveThanks, Mike, and I appreciate everyone being here with us today. We experienced a transformative quarter in Q2, and over these last several weeks we've hit quite a few important milestones. I want to walk you through four key updates right now. First, we've entered into a definitive agreement for what will be the biggest acquisition our company has ever made. Second, alongside that acquisition, we secured a commitment for a substantial new funding source. Third, we hit record volumes throughout our core business verticals. Fourth, we moved our vision forward of bringing together DocGo's technology with its care delivery offerings, building one of the healthcare industry's most innovative delivery platforms. What we have here is an all-encompassing, technology-powered solution that enables us to match the appropriate caregiver with the appropriate individual at the appropriate time in the appropriate setting. It's a platform unlike any other that widens patient reach throughout the entire care spectrum, starting in the hospital and extending into the home. My enthusiasm and confidence regarding the future of this broader set of capabilities have never been greater than they are at this moment. Let's get started. First off, in March we made a formal announcement that the business had started looking into strategic options intended to increase shareholder value. We're sharing today that we've signed a final agreement to bring Hicuity Health, which provides virtual care, into our company; that marks the second big deal we've made in this area within the last nine months. We're planning a webinar for the coming weeks where we'll go deep on Hicuity Health, plus the robust growth and cost synergies this deal delivers, though I'd like to walk you through the highlights now. Hicuity Health, headquartered in St. Louis, is a top supplier of telemedicine for acute and critical care, and it has an impressive set of lasting partnerships and a wide-ranging mix of hospitals and health systems across the U.S. On this call, we want to note that Hicuity has over 400 people on its clinical team. They provide high acuity virtual care, such as Tele-ICU, virtual nursing, and telemetry monitoring. All of that is run through Hicuity's own platform for clinical monitoring and patient management, which is called The Hub. There's a lot of shared DNA between DocGo and Hicuity. Each company has developed its own technology platform that helps make the most of scarce clinical resources — whether that means an advanced practice provider giving critical care in an ICU, or a mobile health clinician delivering preventative care to someone at home. By bringing the Hicuity Hub into DocGo's existing proprietary health tech stack, we'll be better positioned to pair the right provider with the right patient at the right moment in the right place. When you put Hicuity's ability to provide care inside health system environments together with DocGo's mobile, technology-powered approach that delivers care right to people's homes, what we offer becomes something much bigger than any single-stop answer at one stage of a patient's journey. It positions DocGo to reach patients throughout the entire continuum of care, spanning from the hospital all the way to the home. This merger strengthens DocGo's method of delivering care through technology, expands our presence within health systems where our ties already run deep, and creates additional opportunities to widen and cross-sell our robust portfolio of virtual services, in-home care, and remote monitoring. Much like what we're observing with the SteadyMD transaction, we expect to realize substantial operational efficiencies while leveraging our bigger platform to fuel top-line growth going forward. A dedicated team drawn from different parts of the business is already at work charting the integration and expense-cutting work ahead, which touches operations, technology, finance, legal, human resources, and clinical operations. Merging overlapping corporate departments and cutting duplicative administrative costs are among the specific items on our list, along with leveraging one common technology foundation and operating platform, sharpening oversight of outside suppliers and purchasing, driving greater efficiency in clinical operations at both organizations, and expanding opportunities to sell across our combined customer base by offering a broader set of virtual, mobile, and in-home care services. Taking everything into account, we expect the acquisition of Hicuity Health to produce a unified, large-scale mobile and virtual care delivery platform serving health systems, health plans, and digital health companies — an important step in advancing our care-anywhere strategy. Next, I want to walk through the specifics of the Hicuity Health deal and our new funding. Hicuity Health provides an established revenue stream and a demonstrated operating platform; measured on a trailing 12-month basis, Hicuity Health brought in roughly $65 million in revenue and $4.5 million in adjusted EBITDA. Per the agreement’s terms, DocGo will purchase 100% of Hicuity Health on a cash-free basis while taking on the company’s current indebtedness held by Perceptive Advisors. When the deal closes, that debt is projected at about $52 million and will mature in December 2029. Perceptive Advisors will take on Hicuity Health's current debt, and on top of that, they've committed up to another $50 million in financing for DocGo, paid out in several tranches. The first tranche, $12.5 million, gets funded when we sign a services agreement to provide Hicuity Health with management-related services through the pre-closing period. We expect to finalize that agreement shortly. As part of the overall consideration, DocGo is issuing new equity amounting to 2% of its fully diluted outstanding common stock at closing, and all of that goes to Hicuity Health's preferred equity holder. That holder stands to receive an additional 3.5% equity interest if DocGo hits a $250 million market capitalization within three years after closing. Both Perceptive Advisors and Hicuity Health’s preferred equity holder have solid healthcare backgrounds and extensive industry connections. We think our strategic partnerships with these two parties could generate extra value for DocGo in the coming months and years. Third, our business results continue to be solid. Throughout every business line, we hit record volumes in the quarter, with U.S. When we look at year-over-year comparisons, medical transportation is up 15%, in-home healthcare is up 26%, mobile phlebotomy is up 20%, cardiac and remote patient monitoring is up 13%, and virtual care along with lab orders is up 58%. Turning to business development, we've entered into a fresh agreement with a major national health plan to deliver services to its members throughout Pennsylvania. Beyond that, the cumulative count of patients routed to us for care gap closure work has reached 1.7 million since we began, an increase of 100,000 compared with the prior quarter. Our virtual care partner, SteadyMD, continues to impress us with its results. Although telehealth offerings like this usually experience their quietest stretch during the summer, SteadyMD recorded volume on par with what it saw in Q1. During the first part of Q2, we closed a significant contract with a major online pharmacy, and as that relationship expands, it should serve as a major catalyst for growth across the back half of this year. Our work on becoming more efficient keeps moving forward. Sequentially, the improvement in our adjusted EBITDA loss was substantial — it fell by almost 40% versus the prior quarter, going from a $10.3 million loss to $6.3 million in Q2. A big driver behind that gain was a sizable company-wide workforce cut made during the quarter, which took roughly $4.5 million out of annual SG&A. On top of that, several of the AI-driven efficiency programs we talked about three months ago are now beginning to deliver a more meaningful effect. Take our mobile blood-draw operation as one concrete illustration.
Lee Bienstock
executiveOur engineering team created an AI-driven communications system, and at this point it takes care of 60% of incoming patient calls with no need for those patients to talk to a live agent of ours, plus it manages 100% of the calls we make to schedule outbound appointments. On a normal day, more than 1,000 calls get handled by this AI agent with nobody stepping in. Beyond that, AI-based data entry integrations are now responsible for 65% of the orders we receive; by year-end, we expect that figure to climb to 90% of orders, and with our new system, the expense of processing a single order drops from $2 to just pennies. Right now we have more than 10 active programs tied to efficiency of this kind spread across every business line, backing functions that range from determining eligibility to validating patient care reports. Taken together, once these are fully in place over the quarters ahead, we estimate possible yearly savings of roughly $6 million. As we work to bring technology into every corner of our operations, another 20 efficiency-related programs are scheduled to launch in late 2026 and early 2027, and we're eager to tell you more about them during upcoming earnings calls. Earlier today, we updated guidance. Our revenue guidance is fairly steady, excluding any possible effect from Hicuity, but our adjusted EBITDA loss came in wider than we had originally expected, since cost reductions needed more time than we thought to flow through into the financials during the early part of 2026. Even so, we expect the company to reach a positive adjusted EBITDA run rate as we close out the year and to be positioned for a very strong 2027. Fourth, and last, the fulfillment of our vision. Over the past three years, we've been transforming DocGo into a completely vertically integrated, technology-backed healthcare provider capable of serving our health system and insurance payer partners with end-to-end longitudinal care throughout the whole patient journey. Although many companies provide point solutions in healthcare, what we're constructing is a holistic platform that we see as both better and distinctive. As I mentioned when our call began, I've never felt more enthusiastic about the company we're building, one that intends to deliver care wherever patients happen to be. With that, I'll pass things to Norm so he can walk through the financials.
Norm Rosenberg
executiveThanks, Lee, and good afternoon everyone. For Q2 of 2026, total revenue came in at $73.4 million, which compares with $80.4 million during the same quarter in 2025. That drop in revenue on a year-over-year basis stemmed completely from migrant-related projects winding down. If we set aside those migrant-related revenues, we actually posted a 19% year-over-year revenue gain in Q2. Part of that came from our October 2025 purchase of SteadyMD, which contributed $8.9 million of revenues during this year's Q2. If you strip out both the migrant-related revenues from the 2025 period and the SteadyMD revenues from the 2026 period, revenues were still up roughly 5% year-over-year. Medical transportation services revenue rose to $52 million in Q2 of 2026, up from $49.6 million in the second quarter of 2025, edging past Q1's transport revenues to become the highest quarterly figure in DocGo's history. Gains across both large and small U.S. markets pushed revenues higher, with some of the strongest growth coming in markets such as New York, Texas, and Tennessee; we keep seeing rising demand across most of our markets. Mobile health revenue for the second quarter of 2026 totaled $21.4 million, down from $30.8 million in last year's second quarter, once again driven by migrant revenues winding down. Non-migrant mobile health revenues jumped by 78%, fueled by increases in care gap closures, remote patient monitoring, and mobile phlebotomy, along with the inclusion of revenues from SteadyMD, which we acquired during the fourth quarter of 2025. Adjusted EBITDA for the second quarter of 2026 was a -$6.3 million, versus an adjusted EBITDA of -$6.1 million in the second quarter of 2025. Adjusted gross margin, which takes out the impact of depreciation and amortization and is the margin measure we follow most closely, came in at 30.5% in the second quarter of 2026, compared with 31.6% in the second quarter of 2025. In the second quarter of 2026, adjusted gross margins for the medical transportation segment were 32%, versus 31.1% in Q2 of 2025, and slightly above the first quarter of this year. Medical transportation gross margins continue to be held back by effective hourly wages for field labor that ran higher than planned. That said, we've made solid progress toward growing our field headcount during the first half of 2026, and the overtime rate declined once more in the second quarter of 2026 to roughly 8.1%, the lowest level we've seen since the second quarter of 2024. Transport gross margins also took a hit from higher fuel costs, with our per gallon price climbing to $4.27 in Q2 of 2026, versus $3.16 per gallon in last year's second quarter; we estimate fuel costs held back transport gross margins by roughly 60 basis points compared with last year, and the consolidated gross margin by roughly 40 basis points. Mobile health segment adjusted gross margin was 27%, against 32.5% in the second quarter of 2025. SteadyMD's gross margins came in a few points under what we'd typically see. That reflects how aggressively we hired during the first half, both to catch up with the greater demand coming from large customers and to get ready for the higher seasonal volumes we expect in Q3 and Q4. We expect this factor to normalize later in 2026. It was partly offset by bigger relative contributions from our higher-margin mobile health service lines, including remote patient monitoring and mobile phlebotomy. In fact, when you look at the underlying gross margins within the mobile health segment, there's genuinely solid improvement happening there. During last year's second quarter, migrant-related projects accounted for over 60% of mobile health revenues, and those projects carried gross margins of 37.1%. Setting those revenues aside, mobile health gross margins from continuing business lines rose by over 500 basis points, driven by better margins in the healthcare in the home business, while the high-margin mobile phlebotomy and remote patient monitoring lines made up a larger share of mobile health revenues than they did in last year's second quarter. Gross margins did land a bit under expectations, but operating expenses fell as we had anticipated. That came from the cost-cutting steps we've taken so far this year around headcount and vendor spending. Working against that were higher recruiting costs, since we needed to ramp up hiring, onboarding, and training of EMTs and mobile health clinical staff to keep pace with customer demand. In the second quarter, we spent roughly $300,000 on recruiting outreach, which supplemented what our in-house recruiting team was doing. Now that SteadyMD's hiring push is largely behind us, combined with our ongoing cost-cutting through the first half of 2026 and the additional savings still to come from our efficiency portfolio initiatives, we anticipate SG&A will keep declining sequentially as the year progresses. Turning to the remainder of 2026, as Lee said earlier in his remarks and as we noted in our press release, we're narrowing the range of our revenue guidance for 2026 based on what we've already seen in the first half. We now expect full-year revenues of $305 million-$310 million, which sits inside the $300 million-$315 million range we gave on our last call in May. It's also above the $290 million-$300 million we shared in mid-March, as well as our initial guidance for the year of $280 million-$300 million. None of this includes any revenue assumption from Hicuity. Once the timing of the Hicuity acquisition closing becomes clearer, we'll update our revenue guidance to match. Our 2026 guidance also excludes any revenues from migrant-related projects, and on that basis it would represent 21%-23% growth over 2025's base revenues. We now expect a full-year adjusted EBITDA loss of $17 million-$22 million, versus our prior guidance of a $5 million-$10 million adjusted EBITDA loss. Since the EBITDA loss we recorded during 2026's opening six months came in bigger than we had projected, and because the gross margin path we're on right now, even though it's trending higher, remains a bit below our original expectations. Now, moving on to the balance sheet. As of June 30th, 2026, cash and cash equivalents in total, which includes restricted cash along with investments, stood at $48.1 million, a decline from $59.9 million on March 31st, 2026. Available cash came to $25.2 million, falling from $35.7 million as of March 31st. On April 1st, roughly $8 million arrived from migrant-related accounts receivable that New York City's Department of Housing Preservation and Development, HPD, owed us — money we had anticipated receiving during the first quarter. We're continuing efforts to collect what remains of those receivables, though when those future collections will happen can't be predicted. That said, the Hicuity transaction — more specifically the term loan commitment coming from Perceptive, which is set to take the place of our current asset-backed line of credit — marks a significant leap forward for DocGo. This deal will instantly transform our balance sheet, giving us the flexibility required to carry out our growth plans. Looking further ahead, we'll keep pursuing and completing whatever actions are needed to reposition our portfolio of business lines and to reinforce our balance sheet, turning the company into something leaner, more profitable, and simpler for investors and partners to grasp. With that, I'd like to hand the call back to the operator for Q and A. Operator, please proceed.
Ryan MacDonald
analystRyan, thanks for the questions. Let's begin with Hicuity Health. Could you discuss the current customer overlap between our two companies and what cross-selling possibilities that creates? You mentioned $65 million in trailing revenue. How quickly is that business expanding overall? Regarding the deal, what factors are gating or holding back completion by year-end? Thanks.
Lee Bienstock
executiveCertainly. Thanks, Ryan. Good to hear from you. Your line broke up a bit, but I believe we caught the essence of what you asked, so we'll answer as best we can, and naturally, we can follow up on anything. Regarding Hicuity Health, you brought up the existing customer base. Hicuity Health primarily serves hospital systems and health systems. Naturally, we see a lot of common ground with the hospital systems we work with in medical transportation, and Hicuity Health likewise provides Tele-ICU and virtual care services to hospital systems. That overlap strikes us as significant, and of course, there are hospitals we serve that they don't, just as there are hospitals they serve that we don't. We see a strong opportunity in that. On top of that, a lot of what they do includes virtual care delivered at home and managing the transition of patients who are heading home after discharge. In our view, there's a strong chance for us to step in with more hands-on services in the home — things like mobile phlebotomy, along with other preventive and transitional offerings. So in addition to the virtual care synergies that exist with them, with SteadyMD, and across all our virtual care efforts, we see a real opening not just to cross-sell but to go further and give patients at home a complete range of services, covering both virtual and in-person. That piece is truly essential. We recognize that payers and hospital systems alike are zeroed in on that connection between the hospital and the home, and our transitional care management programs for patients being discharged have performed very well. They head into the home, and during that 30-day window after discharge, we're doing follow-up, and for that group, we've managed to bring hospital readmissions down by roughly 50%-60%. So this keeps strengthening the connection we have between the hospital and the home, which in our view is extremely valuable both for hospitals and for the insurance partners we work with. I believe you also raised the question — it was breaking up — but part of what we caught had to do with revenues. As I said during the prepared remarks, Hicuity has roughly $65 million in trailing 12-month revenues. Naturally, we will do whatever we can to back that growth. Our commitment is to provide whatever assistance is necessary, giving them the tools required to expand alongside the clients they already serve, plus a chance for both of us to pursue the market jointly — something that has us genuinely thrilled.
Ryan MacDonald
analystThanks for that detail, Lee. My apologies for cutting in. I hope my audio comes through better at this point. Moving to something else, I wanted to inquire about your remote patient monitoring operation. Clearly, CMS has issued a proposed regulation that could restrict or do away with Medicare reimbursement for RPM come 2027. I'm just wondering what possible dangers this poses to the RPM service you provide. Is Hicuity exposed to this too? I'd just like to hear how you see the matter. Thanks.
Lee Bienstock
executiveYes. Your audio is perfectly audible to us at this moment, Ryan. Thanks. Like you said, there's been some back-and-forth regarding RPM rates, and the RPM program in general, coming from CMS. The initial thing we're at least examining, I believe, is that it does affect RPM, yet a substantial portion of our work accompanies RPM, namely chronic care management along with transitional care management. Such elements carry enormous value, correct? Assisting with the oversight of chronic illnesses and then, once more, handling how patients move from the hospital back home. There's genuinely no talk regarding those categories of programs, once more, all of which focus not merely on watching a patient, but additionally on overseeing a patient. We consider that to be quite a significant difference. Our view is that, in general, I expect eventually that the sector will compensate managing chronic illnesses rather than just watching the information being received. So once more, there's telemetry monitoring that Hicuity performs. We operate our own initiatives on the RPM side, yet everything serves the purpose of not only watching the patient, but assisting with overseeing the patient, and that's where our clinical practice fits in. Thus we aren't just a monitoring firm, but instead, once more, a clinical practice that assists with overseeing chronic illnesses. So that's a major element. Roughly 2,000 patients currently sort of fall within that RPM program. The overwhelming majority of the approximately 55,000 patients we watch, once more, DocGo and ideally additional ones with Hicuity. Yet the overwhelming majority of those individuals are cardiac patients. As I'm sure you're aware, they're implantable cardiac electronic device patients whom we're watching. Once more, there's no talk. Those are clearly heart failure patients whom we're watching routinely. So once more, nothing being discussed there. So on balance, I believe monitoring purely for its own sake, particularly patients, once more, who aren't chronically ill, I think, once more, could face some strain. Yet overseeing patients and their chronic illnesses, I believe eventually will be compensated increasingly, and that's precisely what we do.
Norm Rosenberg
executiveRyan, regarding your other question about obstacles standing in the way of getting the Hicuity deal done — I would say there aren't any that strike me as especially concerning. Clearly, you have to secure approvals from state regulators, and our expectation is that shouldn't prove to be much of a problem, apart from the timing, since that piece is never something you can predict. You also have a few customers in certain places who need to sign off. That said, we've already made contact with those customers, and it's our view that this won't create any particular difficulty on our end.
Ryan MacDonald
analystThanks for that additional response, Norm. I appreciate all of it. I'll get back in line again.
Lee Bienstock
executiveThank you, Ryan.
Richard Close
analystYeah. I appreciate you taking the questions. Nice work on what's been achieved with the acquisition. Perhaps, just to tidy up a bit regarding what Ryan asked. Norm, could you maybe expand on that $65 million in trailing 12-month revenue. What does that look like next to the same 12 months? Has there been growth in the business? Let's begin right there.
Norm Rosenberg
executiveYeah, certainly. I'll look backward and forward too, since as part of how we operate here, we do have their projections, which will need to be validated once we own it. I'd say growth is probably in the low double-digit range; so roughly 10%. Looking ahead, considering what they're anticipating for 2027, you're likely seeing a low double digit, 10%-12% growth rate, and that's what has been occurring. That's been occurring even as certain business lines or service lines have expanded. Others have contracted. They've been shifting away from those. But at the overall level, that $65 million is growing at, I'd say, let's call it a 10%-12% growth rate annually.
Richard Close
analystAll right, that's really useful. Lee, perhaps to clarify your answer to Ryan regarding RPM — are you indicating roughly 2,000 patients could essentially face risk because of this CMS change, while a large majority of 55,000 are cardiac patients where you'd foresee no effect?
Lee Bienstock
executiveExactly right. Yes. So you've got those figures spot on; roughly 55,000 implantable device monitoring patients, once again, that we currently have. Once more, these consist of pacemakers, loop recorders, once again, not part of what's being discussed. Clearly for these patients, having those transmissions monitored regularly is critically important, and that's precisely what our team excels at incredibly well, day in and day out, working alongside cardiac clinics and so on. Once again, irrelevant to any of the conversations taking place today. As you pointed out, we began enrolling patients in RPM and specifically CCM, which we refer to as total care management since, once again, we don't solely concentrate on receiving the data, say a patient's blood pressure or weight. What we do rather is take readings like a person's blood pressure, weight, or pulse oximeter, along with various other data points that may arrive, in order to handle their long-term condition more successfully. Enrollment of patients into that started roughly at the close of last year — I'd say more like the start of this one — so we've kept growing it, though again, our attention isn't limited to just the RPM portion. Our real emphasis falls on the chronic care management and transitional care management sides, and those pieces, again, aren't among the things CMS is talking about. In the end, I do think it makes sense. Again, when I look at this sector and think about what it should be incentivizing, the focus ought to be on rewarding businesses like ours—ones that make a difference in patient outcomes or assist with chronic condition management. Right now, 160 million Americans are living with chronic conditions. It's not enough to simply acquire the data; the real question is what we do with it. Maybe I'm right, maybe not—only time will reveal that—but in my view, this is likely what CMS is driving at: groups, practices, and companies shouldn't be rewarded just for gathering data. Instead, they should be given incentives and rewards for putting that data to work to improve how chronic conditions are managed. When people discuss those RPM rate reductions, they aren't bringing up programs such as CCM, PCM, principal care management, and TCM, transitional care management.
Richard Close
analystAll right, that's useful. So perhaps returning to the idea of selling across both companies once the deals are finalized. I'm wondering, have you spoken with any customers—either DocGo health system clients or those on the Hicuity side—who have already shown some interest in what each business offers? I'm just asking out of curiosity. I realize the transportation side is fairly distinct from Hicuity. So I'd like to know what you've learned up to this point.
Lee Bienstock
executiveYes, good question. Part of the reason is that we've been somewhat cautious, since this was clearly a significant deal that had to remain private and handled carefully. Even so, we've held discussions with certain customers—both those we currently serve in medical transportation and Hicuity customers from whom we require consent for the deal. So talks have happened, and I'd say primarily with our transportation clients. We've built very solid, long-term connections with several large hospital systems for which we've supplied medical transportation across many years. Not long ago I sat down with a president of one very big hospital system we partner with, and there's clearly a demand for helping with staffing and delivering services and support remotely for certain hospitals that struggle to fill in-person roles. So the ties are definitely in place. Maybe medical transportation and, say, virtual Tele-ICU or telemetry monitoring don't overlap much when it comes to service levels, yet the relationships absolutely do. We can go deeper with the hospital systems that recognize we deliver, we execute, we innovate, and whose people love and value our software. Offering them additional solutions that also execute, deliver, provide value, and come with software that performs—I believe that will land very well, and I think we've already begun having some indirect conversations about it, no doubt.
Richard Close
analystAll right, that's useful and —
Lee Bienstock
executiveRichard, let me just tack on one additional thought. Sorry for cutting in. I simply want to tack on one additional thought, and that is, once more, we've observed with SteadyMD and then ideally at this point with Hicuity, in situations where we deliver virtual care, a major point of distinction for us, and we're directing resources toward that, we're making a wager on that, something we feel extremely strongly about, is our capacity not merely to be alongside the patient through virtual means. With Hicuity, say, whether in the hospital or at home, with SteadyMD, to be alongside the patient through virtual means, but our capacity at DocGo to supplement that, to be there with the patient inside their residence, through both virtual and face-to-face means. At present, we have a few of our partners who deliver virtual care, say for Hicuity, yet who also look for services from others to enter the home, say, to perform mobile phlebotomy so as to collect a lab specimen, or to perform wound care, or to change the dressing at the incision site. Once more, every one of those is something we're able to handle in the home. So that represents a really significant element of what we do, once more, both Hicuity and SteadyMD along with our other business lines that either handle medical transportation or deliver care virtually — we can now bring in that in-home care piece, which we regard as an extremely major point of distinction.
Richard Close
analystAll right, that helps. So once this transaction is completed, you brought up a few places where cost reductions could be achieved. You brought up streamlined clinical functions. What I'd like to know is what specifically you mean on that point, because to me it isn't obvious. These look like a pair of separate companies. So what's your thinking on streamlining the clinical function?
Lee Bienstock
executiveYes. That's an excellent question. Thank you; when it comes to clinical operations, often you require a clinical practice group spanning multiple states. For instance, at DocGo, when we acquired SteadyMD, DocGo was delivering clinical services and maintained clinical practice groups across several states, while SteadyMD possessed a clinical practice group covering 50 states. Rather than keeping duplicative clinical practice groups, we combined them into a single clinical practice group licensed in all 50 states. In this situation as well, Hicuity delivers services across 30 states nationwide, once again with a variety of clinical practice groups and clinical infrastructure. Once again, we see a chance to unite them. The capacity to draw on the 400+ clinicians Hicuity employs together with our 500 or 600 clinicians that we currently have, and to form them into a single team and integrate them so we can scale our work; that's once again what happened with SteadyMD. There are duplicative clinical practice groups, and we can then combine the teams and find efficiencies on the clinical side. Beyond that, there's simply an enormous amount of operational efficiencies, once again, that we can take advantage of. Frequently we are working with comparable vendors; now we will be working with perhaps comparable vendors at greater scale, which gives us greater purchasing power. Frequently we are using duplicative systems for cyber and IT. Once again, that lets us collaborate to create synergies from some of that duplication. There will be many areas where we believe we can help both organizations and reduce costs for both organizations by uniting them.
Richard Close
analystPerfect. Thank you. Congrats.
Lee Bienstock
executiveThanks.
David Larsen
analystHello.
Norm Rosenberg
executiveCould you say again what figure was given for the pure organic revenue growth rate during the — Norm Rosenberg responding: My apologies, David.
David Larsen
analystSorry, hello?
Norm Rosenberg
executiveYou're asking for what —
Lee Bienstock
executiveHey Dave. Your line dropped for about a minute there. The question came through to us, but would you mind saying it again, so we can be certain we caught all of it?
David Larsen
analystFor the quarter, what did organic revenue growth come in at? My recollection is that Norm put that figure at 5%.
Norm Rosenberg
executiveCorrect. Let me spell out what organic means here. When we say organic, we're taking the business lines present in both Q2 of 2025 and Q2 of 2026. That requires stripping out the migrant revenue from Q2 of last year, as well as the SteadyMD revenue from Q2 of this year, and that figure came to about 5% year-over-year.
David Larsen
analystMy impression is that you mentioned something — and my assumption is that this will involve an initiative to bring costs down?
Lee Bienstock
executiveDave, we couldn't quite make out what you were saying there. Would you mind asking that again?
David Larsen
analystMy apologies. I’m sorry about this poor line. Are you able to hear me at this point?
Lee Bienstock
executiveYes, we can hear you perfectly now. It’s no issue. We hear you perfectly.
David Larsen
analystOkay. So, reaching EBITDA breakeven as we exit 2026 — could you walk us through the path to that? This quarter showed a fairly sizable loss. Is extra revenue growth part of what you're assuming?
Norm Rosenberg
executiveYeah, David — that's right on both counts. It comes from additional revenue growth, the kind we'd built into our model, and the kind we've been observing — a modest sequential growth rate. Some growth in transport as well. More importantly, we expect decent seasonal upticks at SteadyMD, plus in certain of our care gap closure operations. Our remaining mobile health lines keep delivering solid results, and they're expanding quarter over quarter. Then there's the margin piece; we discussed, or I brought up, how our margin path is trending favorably. It is certainly climbing, though right now it sits below what we'd actually forecast. To illustrate, we believe we were held back by more than 1 point — perhaps 1.25 points, nearly 1.5 points — from the combined effect of fuel costs hitting the transport portion of the business, and SteadyMD's temporarily weaker margins during this year's second quarter. Strip out those items, and simply examine how the business has generally performed, and that points to outperformance of roughly 1.5 points, nearly 2 points better on gross margin; across approximately $75 million-$80 million in revenue, that delivers close to $2 million. That's one more contributor; next, ongoing quarter-over-quarter reductions in SG&A that we anticipate. Several individuals who've departed remain on our payroll owing to severance. Those individuals are phasing out and have begun phasing out. Q3 will show a bigger effect from that. Renegotiating vendor pricing, or swapping one supplier for another at a lower cost, clearly matters too. Every one of those items, as we noted on the prior call, begins to take effect as the year progresses; truly it's all three. A portion of it is greater revenue, a portion is revenue expansion, plus better margin. That, I'd say, is where the largest effects will show up on the gross margin line. And then the ongoing SG&A reduction, and together that sums to landing us quite near a breakeven run rate.
David Larsen
analystAll right, and one final thing, quickly. You mention in the earnings release that there are some fairly strong growth rates being cited. Have you measured how much revenue comes out of these segments, such as mobile phlebotomy, in-home healthcare, cardiac and remote patient monitoring, virtual care, and lab orders? Those revenue growth rates appear fantastic. I suppose what I want to know is how much revenue sits in each of those buckets. Could you give us some parameters around that?
Norm Rosenberg
executiveCertainly. I will provide a broad sense of the quarterly figure and the run rate. Let us begin with remote patient monitoring — the Cardiac RMS business — which brought in roughly $4.5 million during the quarter. Once more, viewed on a run rate basis, that works out to an annualized figure of $18 million. For last year, I believe across full-year 2025, they came in somewhere around the 15 area. That represents a fairly solid percentage growth rate — roughly 20% growth on the top line. SteadyMD came in at about eight. That is a virtual care operation we only bought late last year. It generated approximately $8.9 million. As we noted, and as Lee said in his remarks, there is a seasonal element — summer tends to be somewhat slower. They posted $8.9 million against, I believe, $9.5 million in Q1. After that, you return to that trajectory during the back half of the year. PTI, our mobile phlebotomy operation, during the quarter ran at roughly $1.4 million to $1.5 million. Again, that equates to a run rate of approximately $6 million. That is a company we purchased that I believe was running at an annual rate of about $4 million. You have witnessed a fairly significant jump there, and it is also a very high-margin operation; that should give you a sense of where our bigger business lines stand. The care gap closure business, I believe, is also running somewhere above $1 million to $2 million during the quarter.
David Larsen
analystAll right, that's quite useful. Appreciate it.
Lee Bienstock
executiveThanks a lot, and I appreciate everyone being here with us. We'll talk again before long. Take care.
Operator
operatorEveryone, that wraps up today’s conference call. We appreciate each of you for participating. You’re welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.